- Home
- HTLD vs RIGL Comparison
HTLD vs RIGL Comparison
Compare HTLD & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HTLD | RIGL |
|---|---|---|
| Founded | 1978 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.1M | 628.4M |
| IPO Year | 1995 | 2000 |
Fundamental Metrics
Financial Performance| Metric | HTLD | RIGL |
|---|---|---|
| Price | $9.54 | $26.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $10.00 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 463.1K | 359.7K |
| Earning Date | 05-12-2026 | 05-22-2026 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 19.48 |
| Revenue | ★ $805,709,000.00 | $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.99 | $12.23 |
| P/E Ratio | ★ N/A | $1.35 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $7.00 | $15.50 |
| 52 Week High | $12.13 | $52.24 |
Technical Indicators
Market Signals| Indicator | HTLD | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 35.47 | 25.31 |
| Support Level | $8.31 | $18.14 |
| Resistance Level | $9.60 | $31.26 |
| Average True Range (ATR) | 0.37 | 1.55 |
| MACD | -0.17 | -0.43 |
| Stochastic Oscillator | 9.82 | 3.69 |
Price Performance
Historical ComparisonAbout HTLD Heartland Express Inc.
Heartland Express Inc, along with its subsidiaries, operates as a short, medium, and long-haul truckload carrier and transportation services provider. It mainly provides nationwide asset-based dry van truckload service for shippers across the United States, along with cross-border freight and other transportation services offered through third-party partnerships in Mexico. The group operates under the brand names of Heartland Express, Millis Transfer, Smith Transport, and CFI (for services within Mexico).
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.